LY2928057

Home
Ligands
LY2928057

GtoPdb Ligand ID: 8416

Comment: LY2928057 is an investigational anti-ferroportin monoclonal being developed as a treatment for anemia. A search of patents reveals WO2010065496 A1 as Eli Lilly's application covering the development and use of anti-ferroportin 1 monoclonal antibodies [1]. The HGNC approved gene symbol for ferroportin 1 is SLC40A1.

Summary
Biological activity
Clinical data
References

No information available.

No information available.

Summary of Clinical Use
LY2928057 is being evaluated in a Phase 1 clinical trial as a potential treatment for anemia caused by renal insufficiency (or chrionic kidney disease).

Summary of Clinical Use

LY2928057 is being evaluated in a Phase 1 clinical trial as a potential treatment for anemia caused by renal insufficiency (or chrionic kidney disease).

Mechanism Of Action and Pharmacodynamic Effects
LY2928057 blocks the ferroportin-hepcidin interaction which would result in degradation of the transporter. The physiological effect is an increased circulating iron level.

Mechanism Of Action and Pharmacodynamic Effects

LY2928057 blocks the ferroportin-hepcidin interaction which would result in degradation of the transporter. The physiological effect is an increased circulating iron level.